Intrathecal baclofen treatment in dystonic cerebral palsy: a randomized clinical trial: the IDYS trial

BMC Pediatrics

R Jeroen Vermeulen⁶  Onno Teernstra⁵  Peter M van de Ven⁴  Joke Geytenbeek⁸  Elisabeth Foncke⁷  Rob LM Strijers¹  Willem JR van Ouwerkerk²  Vincent de Groot⁸  Dan Soudant³  Karin Boeschoten⁸  Johannes SH Vles³  Jules G Becher⁸  Laura A Bonouvrié⁸ 

[1] Department of Clinical Neurophysiology, VU University Medical Center, Amsterdam, The Netherlands;Department of Neurosurgery, VU University Medical Center, Amsterdam, The Netherlands;Department of Child Neurology, Maastricht University Medical Center, Amsterdam, The Netherlands;Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands;Department of Neurosurgery, Maastricht University Medical Center, Amsterdam, The Netherlands;Department of Child Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands;Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands;Department of Rehabilitation Medicine, VU University Medical Center, Postbus 7057, 1007, MB Amsterdam, The Netherlands

关键词: Randomized controlled trial;    Intrathecal baclofen;    Goal attainment scaling;    Dyskinesia;    Dystonia;    Cerebral palsy;   

Others  :  1144376
DOI  :  10.1186/1471-2431-13-175

 received in 2013-09-23, accepted in 2013-10-03,  发布年份 2013

【 摘 要 】

Background

Dystonic cerebral palsy is primarily caused by damage to the basal ganglia and central cortex. The daily care of these patients can be difficult due to dystonic movements. Intrathecal baclofen treatment is a potential treatment option for dystonia and has become common practice. Despite this widespread adoption, high quality evidence on the effects of intrathecal baclofen treatment on daily activities is lacking and prospective data are needed to judge the usefulness and indications for dystonic cerebral palsy. The primary aim of this study is to provide level one clinical evidence for the effects of intrathecal baclofen treatment on the level of activities and participation in dystonic cerebral palsy patients. Furthermore, we hope to identify clinical characteristics that will predict a beneficial effect of intrathecal baclofen in an individual patient.

Methods/Design

A double blind placebo-controlled multi-center randomized clinical trial will be performed in 30 children with dystonic cerebral palsy. Patients aged between 4 and 25 years old with a confirmed diagnosis of dystonic cerebral palsy, Gross Motor Functioning Classification System level IV or V, with lesions in the cerebral white matter, basal ganglia or central cortex and who are eligible for intrathecal baclofen treatment will be included. Group A will receive three months of continuous intrathecal baclofen treatment and group B will receive three months of placebo treatment, both via an implanted pump. After this three month period, all patients will receive intrathecal baclofen treatment, with a follow-up after nine months. The primary outcome measurement will be the effect on activities of and participation in daily life measured by Goal Attainment Scaling. Secondary outcome measurements on the level of body functions include dystonia, spasticity, pain, comfort and sleep-related breathing disorders. Side effects will be monitored and we will study whether patient characteristics influence outcome.

Discussion

The results of this study will provide data for evidence-based use of intrathecal baclofen in dystonic cerebral palsy.

Trial registration

Nederlands Trial Register,NTR3642

【 授权许可】

   
2013 Bonouvrié et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Hagberg B, Hagberg G, Olow I, von Wendt L: The changing panorama of cerebral palsy in Sweden. V. The birth year period 1979–82. Acta Paediatr Scand 1989, 78:283-290.
• [2]Bax M, Goldstein M, Rosenbaum PL, Levinton A, Paneth N, Dan B, Jacobsson B, Damiano D: Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol 2005, 47:571-576.
• [3]Krägeloh-Mann I, Helber A, Mader I, Staudt M, Wolff M, Groenendaal F, DeVries L: Bilateral lesions of thalamus and basal ganglia: origin and outcome. Dev Med Child Neurol 2002, 44:477-484.
• [4]Jankovic J: Treatment of hyperkinetic movement disorders. The Lancet Neurology 2009, 8:844-856.
• [5]Sanger TD, Bastian A, Brunstrom J, Damiano D, Delgado M, Dure L, Gaebler-Spira D, Hoon A, Mink JW, Sherman-Levine S, Wlty LJ: Child Motor Study Group. Prospective open-label clinical trial of trihexyphnidyl in children with secondary dystonia due to cerebral palsy. J Child Neurol 2007, 22:530-537.
• [6]Dan B, Motta F, Vles JS, Vloeberghs M, Becher JG, Eunson P, Gautheron V, Lutjen S, Mall V, Pascual-Pascual SI, Pauwels P, Roste GK: Consensus on the appropriate use of intrathecal baclofen (ITB) therapy in paediatric spasticity. Eur J Paediatr Neurol 2010, 14:19-28.
• [7]van Hulst BM, Tel PA, de Groot V, van Ouwerkerk WJ, Vermeulen RJ, Becher JG, Peerdeman SM: Complicaties bij kinderen met intrathecale baclofentherapie en (gerelateerde) verzorgertevredenheid. Tijdschrift voor kindergeneeskunde 2009, 77:191-197.
• [8]Ward A, Hayden S, Dexter M, Scheinberg A: Continuous intrathecal baclofen for children with spasticity and/or dystonia: Goal attainment and complications associated with treatment. J Paediatr Child Health 2009, 45:720-726.
• [9]Albright AL, Barry MJ, Fasick P, Barron W, Shultz B: Continuous intrathecal baclofen infusion for symptomatic generalized dystonia. Neurosurgery 1996, 38:934-939.
• [10]Albright AL, Barry MJ, Painter MJ, Shultz B: Infusion of intrathecal baclofen for generalized dystonia in cerebral palsy. J Neurosurg 1998, 88:73-76.
• [11]Albright AL, Barry MJ, Shafron DH, Ferson SS: Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001, 43:652-657.
• [12]World Health Organisation: International Classification of Functioning. Geneva: Disability and Health; 2001. Ref Type: Catalog
• [13]Turner-Stokes L: Goal attainment scaling (GAS) in rehabilitation: a practical guide. Clin Rehabil 2009, 23:362-370.
• [14]Bovend’Eerdt TJH, Botell RE, Wade DT: Writing SMART rehabilitation goals and achieving goal attainment scaling: a practical guide. Clin Rehabil 2009, 23:352-361.
• [15]Steenbeek D, Ketelaar M, Galama K, Gorter JW: Goal attainment scaling in paediatric rehabilitation: a critical review of the literature. Dev Med Child Neurol 2007, 49:550-556.
• [16]Steenbeek D, Ketelaar M, Galama K, Gorter JW: Goal attainment scaling in paediatric rehabilitation: a report on the clinical training of an interdisciplinary team. Child: care, health and development 2008, 34:521-529.
• [17]Steenbeek D, Ketelaar M, Lindeman E, Galama K, Gorter JW: Interrater reliability of goal attainment scaling in rehabilitation of children with cerebral palsy. Arch Phys Med Rehabil 2010, 91:429-435.
• [18]Choate R, Smith A, Cardillo JE, Thompson L: Training in the use of Goal Attainment Scaling. Community Ment Health J 1981, 17:171-181.
• [19]Steenbeek D, Meester-Delver A, Becher JG, Lankhorst GJ: The effect of botulinum toxin type A treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling. Clin Rehabil 2005, 19:274-282.
• [20]Monbaliu E, Ortibus E, De Cat J, Dan B, Heyrman L, Prinzie P, De Cock P, Feys H: The Dyskinesia Impairment Scale: a new instrument to measure dystonia and choreoathetosis in dyskinetic cerebral palsy. Dev Med Child Neurol 2012, 54:278-283.
• [21]Barry MJ, VanSwearingen JM, Albright AL: Reliability and responsiveness of the Barry-Albright Dystonia scale. Dev Med Child Neurol 1999, 41:404-411.
• [22]Hoving MA, van Kranen-Mastenbroek VHJM, van Raak EPM, Spincemaille GHJJ, Hardy ELM, Vles JSH: On behalf of the Dutch Study Group on Child Spasticity. Placebo controlled utility and feasibility study of the H-reflex and flexor reflex in spastic children treated with intrathecal baclofen. Clin Neurophysiol 2006, 117:1508-1517.
• [23]Bour LJ, Koelman JHTM, van Bruggen GJ, Speelman JD, Ongerboer de Visser BW: Soleus H-reflex tests in spasticity and dystonia: A computerized analysis. J Electromyogr Kinesiol 1991, 1:9-19.
• [24]Becher JG, Doorenbosch C, Folmer K, Scholtes VAB, Voorman JM, Wolterbeek N: Handleiding standaard lichamelijk onderzoek bij kinderen met een centraal motorische parese. Amsterdam: Reed business; 2011.
• [25]Scholtes VAB, Dallmeijer AJ, Becher JG: The spasticity test: a clinical instrument to measure spasticity in children with cerebral palsy. The effectiveness of multilevel botulinum toxin type A and comprehensive rehabilitation in children with cerebral palsy [dissertation]. Amsterdam: VU University Medical Center; 2007.
• [26]Scholtes VAB, Becher JG, Beelen A, Lankhorst GJ: Clinical assessment of spasticity in children with cerebral palsy: a critical review of available instruments. Dev Med Child Neurol 2006, 48:64-73.
• [27]Sandella DE, O’Brien LM, Shank LK, Warschausky SA: Sleep and quality of life in children with cerebral palsy. Sleep Med 2011, 12:252-256.
• [28]Bensmail D, Quera Salva MA, Roche N, Benyahia S, Bohic M, Denys P, Bussel B, Lofaso F: Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. Neurology 2006, 67:1432-1436.
• [29]Bensmail D, Marquer A, Roche N, Godard A, Lofaso F, Quera Salva MA: Pilot study assessing the impact of intrathecal baclofen administration mode on sleep-related respiratory parameters. Arch Phys Med Rehabil 2012, 93:96-99.
• [30]Chervin RD, Hedger K, Dillon JI, Pituch KJ: Pediatric Sleep Questionnaire (PSQ): validity and reliability of scales for sleep-disordered breathing, snoring, sleepiness and behavioral problems. Sleep Med 2000, 1:21-32.
• [31]Palisano RJ, Hanna SE, Rosenbaum PL, Russel DJ, Walter EP, Raina PS, Galuppi BE: Validation of a model of gross motor function for children with cerebral palsy. Phys Ther 2000, 80:974-985.
• [32]Wood E, Rosenbaum PL: The gross motor function classification system for cerebral palsy: a study of reliability and stability over time. Dev Med Child Neurol 2000, 42:292-296.
• [33]Eliasson AC, Krumlinde-Sundholm L, Rösblad B, Beckung E, Arner M, Ohrvall AM, Rosenbaum PL: The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol 2006, 48:549-554.
• [34]Morris C, Kurinczuk JJ, Fitzpatrick R, Rosenbaum PL: Reliability of the manual ability classification system for children with cerebral palsy. Dev Med Child Neurol 2006, 48:950-953.
• [35]Voorman JM, Dallmeijer AJ, van Eck M, Schuengel C, Becher JG: Social functioning and communication in children with cerebral palsy: association with disease characteristics and personal and environmental factors. Dev Med Child Neurol 2009, 52:441-447.
• [36]Geytenbeek JJM, Heim MMJ, Vermeulen RJ, Oostrom KJ: Assessing comprehension of spoken language in nonspeaking children with cerebral palsy: application of a newly developed computer based instrument. Augment Altern Commun 2010, 26:97-107.
• [37]Feldman AB, Haley SM, Coryell J: Concurrent and construct validity of the Pediatric Evaluation of Disability Inventory. Phys Ther 1990, 70:602-610.
• [38]Haley SM, Coster WJ, Ludlow LH, Haltiwanger JT, Andrellos PJ: Pediatric Evaluation of Disability Inventory (PEDI): development, standardization and administration manual. Boston, MA: PEDI Research Group, Department of Rehabilitation Medicine; 1992.